

<p style="text-align: center;">LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i></p> <p style="text-align: center;">JUN 04 2001 U.S. PATENT & TRADEMARK OFFICE O I P E C 113</p>		ATTY. DOCKET NO. 9632-006-999	APPLICATION NO. 09/724,406
		APPLICANT Francisco et al.	
		FILING DATE November 28, 2000	GROUP 1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AD	AA 5,165,923	November 24, 1992	Thorpe et al.			
	AB 5,866,372	February 2, 1999	Stein et al.			
↓	AC 6,033,876	March 7, 2000	Lemke et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

AD	AD	Arndt et al., 1999, "A Bispecific Diabody That Mediates Natural Killer Cell Cytotoxicity Against Xenotransplanted Human Hodgkin's Tumors," Blood 94(8):2562-2568
	AE	Barth et al., 2000, "Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice," Blood 95:3909-3914
	AF	Bowen et al., 1993, "Functional Effects of CD30 on a Large Granular Lymphoma Cell Line, YT," J. Immunol. 151:5896-5906
	AG	Cerutti et al., 1998, "CD30 Is a CD40-Inducible Molecule that Negatively Regulates CD40-Mediated Immunoglobulin Class Switching in Non-Antigen-Selected Human B Cells," Immunity 9:247-256
	AH	Del Prete et al., 1995, "CD30-mediated Signaling Promotes the Development of Human T Helper Type 2-like T Cells," J. Exp. Med. 182:1655-1661
	AI	Dürkop et al., 1992, "Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease.,," Cell 68:421-427
	AJ	Engert et al., 1990, "Evaluation of Ricin A Chain-containing Immunotoxins Directed against the CD30 Antigen as Potential Reagents for the Treatment of Hodgkin's Disease," Cancer Res. 50:84-88
	AK	Engert et al., 1999, "Treatment of Advanced Hodgkin's Lymphoma: Standard and Experimental Approaches," Seminars on Hematology 36(3):282-289
	AL	Falini et al., 1992, "In vivo targeting of Hodgkin and Reed-Sternberg cells of Hodgkin's disease with monoclonal antibody Ber-H2 (CD30): immunohistological evidence," British J. Haemat. 82:38-45
	AM	Falini et al., 1992, "Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin," The Lancet 339:1195-1196
↓	AN	Franke et al., 2000, "Characterization of the CD30L Binding Domain on the Human CD30 Molecule Using Anti-CD30 Antibodies," Hybridoma 19:43-48

✓ ND	AO	Grell et al., 1999, "Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF," <i>EMBO J.</i> 18(11):3034-3043
O I P E JUN 4 2001 PATENT & TRADEMARK OFFICE	AP	Gruss et al., 1994, "Pleiotrophic Effects of the CD30 Ligand on CD30-Expressing Cells and Lymphoma Cell Lines," <i>Blood</i> 83(8):2045-2056
O I P E JUN 4 2001 PATENT & TRADEMARK OFFICE	AQ	Hansen et al., 1991, "Antibody-enhanced shedding of the CD30 (Ki-1) antigen and biochemical analysis of its soluble form," <i>Immunobiol.</i> 183:214
O I P E JUN 4 2001 PATENT & TRADEMARK OFFICE	AR	Hecht et al., 1985, "Production and Characterization of a Monoclonal Antibody That Binds Reed-Sternberg Cells," <i>J. Immunol.</i> 134(6):4231-4236
O I P E JUN 4 2001 PATENT & TRADEMARK OFFICE	AS	Horn-Lohrens et al., 1995, "Shedding of the Soluble Form of CD30 From the Hodgkin-Analogose Cell Line L540 is Strongly Inhibited by a new CD30-Specific Antibody (Ki-4)," <i>Int. J. Cancer</i> 60:539-544
O I P E JUN 4 2001 PATENT & TRADEMARK OFFICE	AT	Hsu et al., 1987, "Effect of Monoclonal Antibodies Anti-2H9, Anti-IRac, and Anti-HeFi-1 on the Surface Antigens of Reed-Sternberg Cells," <i>JNCI</i> 79(5):1091-1099
	AU	Hübinger et al., 1999, "The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation," <i>Exp. Hematol.</i> 27:1796-1805
	AV	Josimovic-Alasevic et al., 1989, "Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay," <i>Eur. J. Immunol.</i> 19:157-162
	AW	Leca et al., 1994, "A Monoclonal Antibody to the Hodgkin's Disease-Associated Antigen CD30 Induces Activation and Long-Term Growth of Human Autoreactive $\gamma\delta$ T Cell Clone," <i>Cell. Immunol.</i> 156:230-239
	AX	Masuda et al., 1998, "Dual action of CD30 antigen: Anti-CD30 antibody induced apoptosis and interleukin-8 secretion in Ki-1 lymphoma cells," <i>Int. J. Hematol.</i> 67:257-265
	AY	May et al., 1990, "Evaluation of ricin A chain-containing immunotoxins directed against different epitopes on the delta-chain of cell surface-associated IgD on murine B cells," <i>J. Immunol.</i> 144:3637-3642
	AZ	Mir et al., 2000, "Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells," <i>Blood</i> 96(13):4307-4312
	BA	Nawrocki et al., "Biochemical and Structural Properties of a Hodgkin's Disease-Related Membrane Protein," <i>J. Immunol.</i> 141:672-680
	BB	Pallesen, 1990, "The diagnostic significance of the CD30 (Ki-1) antigen," <i>Histopathology</i> 16:409-413
	BC	Powell et al., 1998, "Construction and expression of a soluble form of human CD30 ligand with functional activity," <i>J. Leukocyte Biology</i> 63:752-757
	BD	Press et al., 1988, "Ricin A-chain containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells," <i>J. Immunol.</i> 141:4410-4417
	BE	Renner et al., 2000, "Initiation of humoral and cellular immune responses in patients with refractory Hodgkin's disease by treatment with an anti-CD16/CD30 bispecific antibody," <i>Cancer Immunol. Immunother.</i> 49:173-180
	BF	Schwab et al., 1982, "Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells," <i>Nature</i> 299:65-67
	BG	Schwarting et al., 1989, "BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope," <i>Blood</i> , <i>Blood</i> 74:1678-1689
↓	BH	Smith et al., 1993, "CD30 Antigen, a Marker for Hodgkin's Lymphoma, Is a Receptor Whose Ligand Defines an Emerging Family of Cytokines with Homology to TNF," <i>Cell</i> 73:1349-1360

<i>NAD</i>	BI	Tian et al., 1995, "In vivo Antitumor Effects of Unconjugated CD30 Monoclonal Antibodies on Human Anaplastic Large-Cell Lymphoma Xenografts," <i>Cancer Res.</i> 55:5335-5341
	BJ	Tsutsumi et al., 2000, "Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity," <i>Proc. Natl. Acad. Sci. USA</i> 97:8548-8553
	BK	Tutt et al., 1998, "Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors," <i>J. Immunol.</i> 161:3176-3185
EXAMINER	<i>Notchie A. Orr</i> DATE CONSIDERED <i>7-5-01</i>	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.